iNGR-modified PEG-PLGA nanoparticles that recognize tumor vasculature and penetrate gliomas

Kang, Ting; Gao, Xiaoling; Hu, Quanyin; Jiang, Di; Feng, Xingye; Zhang, Xue; Song, Qing; Yao, Lei; Huang, Meng; Jiang, Xinguo; Pang, Zhiqing; Chen, Hongzhuan; Chen, Jun

doi:10.1016/j.biomaterials.2014.01.082

Cited by 82 publications

(83 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional active targeting using moieties that preferentially bind to receptors on the cerebral endothelial cells or overexpressed on brain tumor cells did indeed improve the therapeutic potential of nanomedicines due to preferential distribution to and within the brain tumor area: in all the studies with intravenously administered actively targeted nanomedicines, the median survival times were longer than their actively untargeted counterparts and noticeably longer than the untreated controls [75,[86][87][88].…”

Section: Systemic Delivery Of Nanomedicinesmentioning

confidence: 97%

“…In this sense, peptides containing the amino acid sequence Arg-Gly-Asp (RGD) have been coupled to the surface of distinct nanomedicines to bind to αVβ3 integrin [73,74]. Another tripeptide Asn-Gly-Arg (NGR) has been conjugated to different nanomedicines to target aminopeptidase N (CD 13) [75]. Moreover, the ability of the F3 peptide and the AS1411 aptamer to bind to nucleolin has been exploited to actively target nanomedicines to the brain tumor tissue [76,77].…”

Section: Systemic Delivery Of Nanomedicinesmentioning

confidence: 99%

See 1 more Smart Citation

Managing CNS Tumors: The Nanomedicine Approach

Aparicio-Blanco¹,

Torres-Suárez²

2017

New Approaches to the Management of Primary and Secondary CNS Tumors

View full text Add to dashboard Cite

Albeit the rapidly evolving knowledge about tumor biochemistry enables various new drug molecules to be designed as treatments, malignant central nervous system (CNS) tumors remain untreatable due to the failure to expose the entire tumor to such therapeutics at pharmacologically meaningful quantities. Therefore, drug delivery in CNS tumors must be properly addressed, as otherwise, novel therapies will continue to fail. In this regard, nanomedicine poses an appealing platform for efficient drug delivery to the CNS, since it may be targeted to improve the drug availability in the site of action, which would be translated into lower drug doses and fewer side effects. Hence, the accumulation of data about the CNS physiology and their relevant receptors, the widening therapeutic armamentarium of drugs potentially useful in CNS chemotherapy and the alternative routes for administration may envisage nanomedicines as a forthcoming routine approach. Indeed, on the basis of the promising results gathered from preclinical studies of nanomedicine-based therapy both systemically and locally administered, some nanomedicines have already been approved for clinical trials in a variety of CNS tumor conditions to serve as the first steps in the translation of nanotherapy to clinic. Their outcome will steer research directions for further improvements.

show abstract

Section: Systemic Delivery Of Nanomedicinesmentioning

confidence: 97%

Section: Systemic Delivery Of Nanomedicinesmentioning

confidence: 99%

Managing CNS Tumors: The Nanomedicine Approach

Aparicio-Blanco¹,

Torres-Suárez²

2017

New Approaches to the Management of Primary and Secondary CNS Tumors

View full text Add to dashboard Cite

show abstract

“…expressed, were used as the models of tumor cells and tumor neovascular endothelial cells, respectively. 20,22,23,47,48 Low cytotoxicity of the carrier itself is a primary concern in the development of a drug delivery system. Figure 6A and B shows the viability of MDA-MB-231 cells and HUVECs incubated with HMSN, pHMSN, or tHMSN for 48 hours (as determined by CCK-8 assay).…”

Section: Evaluation Of Drug-loading and Drug-release Propertiesmentioning

confidence: 99%

Single peptide ligand-functionalized uniform hollow mesoporous silica nanoparticles achieving dual-targeting drug delivery to tumor cells and angiogenic blood vessel cells

Liu¹,

Chen²,

Xu³

et al. 2015

IJN

View full text Add to dashboard Cite

Background The purpose of this study was to construct hollow mesoporous silica nanoparticles (HMSN) decorated with tLyp-1 peptide (tHMSN) for dual-targeting drug delivery to tumor cells and angiogenic blood vessel cells. Methods HMSN were synthesized de novo using a novel cationic surfactant-assisted selective etching strategy and were then modified with tLyp-1. Multiple methods, including transmission electron microscopy, X-ray photoelectron spectroscopy, thermogravimetric analysis, bicinchoninic acid assay, and nitrogen adsorption and desorption isotherms, were used to characterize the tHMSN. Doxorubicin were chosen as the model cargo, and the uptake of doxorubicin-loaded tHMSN into MDA-MB-231 cells and human umbilical vein endothelial cells (HUVECs), as models of tumor cells and tumor neovascular endothelial cells, respectively, were observed and detected by confocal laser scanning microscopy and flow cytometry. An in vitro pharmacodynamic study and a study of the mechanism via which the nanoparticles were endocytosed were also performed. Results HMSN with a highly uniform size and well oriented mesopores were synthesized. After tHMSN were characterized, enhanced uptake of the cargo carried by tHMSN into MDA-MB-231 cells and HUVECs compared with that of their unmodified counterparts was validated by confocal laser scanning microscopy and flow cytometry at the qualitative and quantitative levels, respectively. Further, the pharmacodynamic study suggested that, compared with their unmodified counterparts, doxorubicin-loaded tHMSN had an enhanced inhibitory effect on MDA-MB-231 cells and HUVECs in vitro. Finally, a preliminary study on the mechanism by which the nanoparticles were endocytosed indicated that the clathrin-mediated endocytosis pathway has a primary role in the transport of tHMSN into the cytoplasm. Conclusion tHMSN might serve as an effective active targeting nanocarrier strategy for anti-mammary cancer drug delivery.

show abstract

“…1 In the past decade, numerous novel strategies based on various nanomaterials have been developed to conquer the highly mortal brain tumors. [2][3][4][5] Interesting topics in this field include the targeted and controlled delivery system of anticancer drugs; [6][7][8][9] photodynamic, photothermal, and magnetothermal therapy of tumors; [10][11][12][13][14][15][16] and MRI, CT, and fluorescent imaging of brain tumors. [17][18][19][20][21][22] Among various nanomaterials, magnetic nanoparticles (NPs) such as superparamagnetic iron oxide NPs (SPIONs) are the most extensively studied.…”

Section: Introductionmentioning

confidence: 99%

Water-soluble l-cysteine-coated FePt nanoparticles as dual MRI/CT imaging contrast agent for glioma

Liang¹,

Zhou²,

Wang³

et al. 2015

IJN

View full text Add to dashboard Cite

Nanoparticles (NPs) are advantageous for the delivery of diagnosis agents to brain tumors. In this study, we attempted to develop an l -cysteine coated FePt (FePt-Cys) NP as MRI/CT imaging contrast agent for the diagnosis of malignant gliomas. FePt-Cys NPs were synthesized through a co-reduction route, which was characterized by transmission electron microscopy, high-resolution transmission electron microscopy, powder X-ray diffraction, Fourier transform infrared spectroscopy, and dynamic light scattering. The MRI and CT imaging ability of FePt-Cys NPs was evaluated using different gliomas cells (C6, SGH44, U251) as the model. Furthermore, the biocompatibility of the as-synthesized FePt-Cys NPs was evaluated using three different cell lines (ECV304, L929, and HEK293) as the model. The results showed that FePt-Cys NPs displayed excellent biocompatibility and good MRI/CT imaging ability, thereby indicating promising potential as a dual MRI/CT contrast agent for the diagnosis of brain malignant gliomas.

show abstract

iNGR-modified PEG-PLGA nanoparticles that recognize tumor vasculature and penetrate gliomas

Cited by 82 publications

References 56 publications

Managing CNS Tumors: The Nanomedicine Approach

Managing CNS Tumors: The Nanomedicine Approach

Single peptide ligand-functionalized uniform hollow mesoporous silica nanoparticles achieving dual-targeting drug delivery to tumor cells and angiogenic blood vessel cells

Water-soluble l-cysteine-coated FePt nanoparticles as dual MRI/CT imaging contrast agent for glioma

Contact Info

Product

Resources

About

iNGR-modified PEG-PLGA nanoparticles that recognize tumor vasculature and penetrate gliomas

Cited by 82 publications

References 56 publications

Managing CNS Tumors: The Nanomedicine Approach

Managing CNS Tumors: The Nanomedicine Approach

Single peptide ligand-functionalized uniform hollow mesoporous silica nanoparticles achieving dual-targeting drug delivery to tumor cells and&nbsp;angiogenic blood vessel cells

Water-soluble l-cysteine-coated FePt nanoparticles as dual MRI/CT imaging contrast agent for glioma

Contact Info

Product

Resources

About

Single peptide ligand-functionalized uniform hollow mesoporous silica nanoparticles achieving dual-targeting drug delivery to tumor cells and angiogenic blood vessel cells